Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innova...
DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition ...
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't k...
Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for, and type 2 diabetes (T2D) r...
Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis – &ndas...
Join us for an in-depth conversation with Chua Keng Hock as we explore the challenges, strategies, and future prospects of the biopharma industry in today'...
Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity, today announ...
To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helpi...
Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce the results of a recent sc...
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead prog...
Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Bimagrumab...
In a career at Franklin Templeton spanning 35 years, Johnson has been a key driver in the company's transformation to what is now one of the largest global...
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatm...
© 2026 Biopharma Boardroom. All Rights Reserved.
